The Full Wiki

More info on SR-48692

SR-48692: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

SR-48692
Systematic (IUPAC) name
2-([1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino)admantane-2-carboxylic acid
Identifiers
CAS number 146362-70-1
ATC code  ?
PubChem 119192
Chemical data
Formula C 32H31ClN4O5  
Mol. mass 587.064
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

SR-48692 is a drug which acts as a selective, non-peptide antagonist at the neurotensin receptor NTS1, and was the first non-peptide antagonist developed for this receptor.[1][2] It is used in scientific research to explore the interaction between neurotensin and other neurotransmitters in the brain,[3][4][5][6][7][8] and produces anxiolytic, anti-addictive and memory-impairing effects in animal studies.[9][10][11][12]

References

  1. ^ Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A (January 1993). "Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor". Proceedings of the National Academy of Sciences of the United States of America 90 (1): 65–9. PMID 8380498.  
  2. ^ Gully D, Jeanjean F, Poncelet M, Steinberg R, Soubrié P, Le Fur G, Maffrand JP (1995). "Neuropharmacological profile of non-peptide neurotensin antagonists". Fundamental & Clinical Pharmacology 9 (6): 513–21. PMID 8808171.  
  3. ^ Rostene W, Azzi M, Boudin H, Lepee I, Souaze F, Mendez-Ubach M, Betancur C, Gully D (April 1997). "Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions". Annals of the New York Academy of Sciences 814: 125–41. PMID 9160965.  
  4. ^ Jolas T, Aghajanian GK (August 1997). "Neurotensin and the serotonergic system". Progress in Neurobiology 52 (6): 455–68. PMID 9316156.  
  5. ^ Dobner PR, Deutch AY, Fadel J (June 2003). "Neurotensin: dual roles in psychostimulant and antipsychotic drug responses". Life Sciences 73 (6): 801–11. PMID 12801600.  
  6. ^ Chen L, Yung KK, Yung WH (September 2006). "Neurotensin selectively facilitates glutamatergic transmission in globus pallidus". Neuroscience 141 (4): 1871–8. doi:10.1016/j.neuroscience.2006.05.049. PMID 16814931.  
  7. ^ Petkova-Kirova P, Rakovska A, Della Corte L, Zaekova G, Radomirov R, Mayer A (September 2008). "Neurotensin modulation of acetylcholine, GABA, and aspartate release from rat prefrontal cortex studied in vivo with microdialysis". Brain Research Bulletin 77 (2-3): 129–35. doi:10.1016/j.brainresbull.2008.04.003. PMID 18721670.  
  8. ^ Petkova-Kirova P, Rakovska A, Zaekova G, Ballini C, Corte LD, Radomirov R, Vágvölgyi A (December 2008). "Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders". Neurochemistry International 53 (6-8): 355–61. doi:10.1016/j.neuint.2008.08.010. PMID 18835308.  
  9. ^ Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrié P (December 2001). "Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery". Neuroscience and Biobehavioral Reviews 25 (7-8): 619–26. PMID 11801287.  
  10. ^ Tirado-Santiago G, Lázaro-Muñoz G, Rodríguez-González V, Maldonado-Vlaar CS (October 2006). "Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats". Behavioral Neuroscience 120 (5): 1093–102. doi:10.1037/0735-7044.120.5.1093. PMID 17014260.  
  11. ^ Felszeghy K, Espinosa JM, Scarna H, Bérod A, Rostène W, Pélaprat D (December 2007). "Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference". Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 32 (12): 2601–10. doi:10.1038/sj.npp.1301382. PMID 17356568.  
  12. ^ Lévesque K, Lamarche C, Rompré PP (October 2008). "Evidence for a role of endogenous neurotensin in the development of sensitization to the locomotor stimulant effect of morphine". European Journal of Pharmacology 594 (1-3): 132–8. doi:10.1016/j.ejphar.2008.07.048. PMID 18706409.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message